{"organizations": ["Boehringer", "Barclays"], "uuid": "9212f90e0a6fe23236bdd0a6094d1dbbc89105f7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.finance.yahoo.com", "main_image": "https://s1.yimg.com/bt/api/res/1.2/M7vS95b2fvSzHFeFStPk0A--/YXBwaWQ9eW5ld3NfbGVnbztxPTc1O3c9NjAw/http://l.yimg.com/os/mit/media/m/social/images/social_default_logo-1481777.png", "site_section": "https://uk.finance.yahoo.com/news/provider-targetukfocus/?format=rss", "section_title": "Finance News | Reuters - UK Focus - Yahoo! UK & Ireland Finance", "url": "https://uk.finance.yahoo.com/news/buzz-hikma-2nd-top-ftse-072857554.html", "country": "US", "title": "BUZZ-Hikma: 2nd top FTSE gainer after Barclays lauds Boehringer deal", "performance_score": 0, "site": "yahoo.com", "participants_count": 0, "title_full": "BUZZ-Hikma: 2nd top FTSE gainer after Barclays lauds Boehringer deal", "spam_score": 0.0, "site_type": "news", "published": "2015-09-02T10:30:00.000+03:00", "replies_count": 0, "uuid": "9212f90e0a6fe23236bdd0a6094d1dbbc89105f7"}, "author": "", "url": "https://uk.finance.yahoo.com/news/buzz-hikma-2nd-top-ftse-072857554.html", "ord_in_thread": 0, "title": "BUZZ-Hikma: 2nd top FTSE gainer after Barclays lauds Boehringer deal", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "255.10 +1.9500 \n** Pharma co Hikma up c.5.6 pct, 2nd top gainer on London's bluechip index & on track for sharpest move in over 1 mnth after brokerage TP hike \n** Barclays (LSE: BARC.L - news ) says U.S (Other OTC: UBGXF - news ) . generics deal, announced in July, transforms Hikma's long-term growth profile and ups TP on stock to 2760p from 2050p, keeps \"overweight\" rating \n** 8 of 12 brokerages rate the stock \"buy\" or higher, 3 \"hold\" and 1 \"sell\" or lower; their median PT is $38.35 \n** Stock moved up by slew of brokerage after co bought Boehringer Ingleheim's specialty generics drugs business in the U.S. for $2.65 bln \n** Deal moves up outer FY earnings by >20 pct & revolutionizes future opportunities, Barclays writes \n** Jordanian co's stock up 12.64 pct YTD, contrasting a c.7.7 pct fall in the FTSE-100 index \n** Valuations in health cos across globe buoyed by a surge in deal-making this year; sector top in global M&A until recently overtaken by the commodity deal frenzy (esha.vaish@thomsonreuters.com)", "external_links": [], "published": "2015-09-02T10:30:00.000+03:00", "crawled": "2015-09-02T10:37:16.788+03:00", "highlightTitle": ""}